Market News
Global Hemoglobinopathy Market: Key Developments
- The key players in the market are focusing on growth strategies such as acquisition to enhance their product portfolio, which is expected to drive the global hemoglobinopathy market growth over the forecast period.
- For instance, in September 2022, Novo Nordisk A/S, a global healthcare company, and Forma Therapeutics, Holdings Inc., a biotech company, announced that they have entered into a definitive agreement, under which Novo Nordisk will acquire Forma Therapeutics, Holdings Inc. The acquisition of Forma Therapeutics, Holdings Inc., including its lead development candidate, etavopivat, is aligned with Novo Nordisk A/S’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies.
- On April 12 2023, ECHO India, a non-profit organization committed to strengthening healthcare capacity in India, has teamed up with the Post Graduate Institute of Child Health (PGICH) Noida, to launch a nationwide program focused on the Prevention and Control of Beta Thalassemia and Other Hemoglobinopathies.
- In June 2020, CRISPR Therapeutics, a gene editing company, and Vertex Pharmaceuticals Incorporated a biotechnology company, announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD), and highlighted recent progress in the CTX001 development program.
- In June 2022, Fulcrum Therapeutics, a clinical stage biopharmaceutical company, announced clinical proof-of-concept data from the ongoing Phase 1b trial of FTX-6058 for the treatment of sickle cell disease (SCD).
U.S.: 
U.K. : 
India : 
